We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-11.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
-$1.54B
Cap. Flow
-$210M
Cap. Flow %
-2.97%
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$67.9M
2
PFE icon
Pfizer
PFE
+$40.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.9M
4
HRMY icon
Harmony Biosciences
HRMY
+$26M
5
CRL icon
Charles River Laboratories
CRL
+$25.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$100M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.4M
3
ABBV icon
AbbVie
ABBV
+$47.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.26%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
76
DELISTED
Kezar Life Sciences
KZR
$25.1M 0.35%
303,500
-163,315
-35% -$14.4M
CLDX icon
77
Celldex Therapeutics
CLDX
$2.81B
$24.9M 0.35%
+925,000
New +$26.9M
PEN icon
78
Penumbra
PEN
$12.5B
$24M 0.34%
192,588
-1,066
-0.6% -$169K
GBIO
79
DELISTED
Generation Bio
GBIO
$23.8M 0.34%
362,728
-5,490
-1% -$359K
TFX icon
80
Teleflex
TFX
$5.97B
$23.6M 0.33%
95,984
-1,730
-2% -$504K
BNTX icon
81
BioNTech
BNTX
$23.4B
$22.5M 0.32%
151,200
+39,434
+35% +$6.03M
BEAM icon
82
Beam Therapeutics
BEAM
$2.74B
$22.2M 0.31%
572,621
-10,200
-2% -$405K
MGNX icon
83
MacroGenics
MGNX
$280M
$21.6M 0.31%
7,325,514
– –
HCM icon
84
HUTCHMED
HCM
$1.94B
$21.4M 0.3%
1,756,307
+5,617
+0.3% +$71.5K
CVS icon
85
CVS Health
CVS
$137B
$21.2M 0.3%
229,153
-3,202
-1% -$313K
CSTL icon
86
Castle Biosciences
CSTL
$724M
$20.7M 0.29%
941,059
+333,445
+55% +$7.75M
PRCT icon
87
Procept Biorobotics
PRCT
$1.07B
$19.5M 0.28%
595,380
+309,305
+108% +$11.3M
HOLX
88
DELISTED
Hologic
HOLX
$18.8M 0.27%
270,825
-4,958
-2% -$368K
TMDX icon
89
Transmedics
TMDX
$2.53B
$18.2M 0.26%
579,887
-1,142
-0.2% -$30.5K
MRSN
90
DELISTED
Mersana Therapeutics
MRSN
$18M 0.25%
155,808
-2,352
-1% -$221K
RMD icon
91
ResMed
RMD
$28.6B
$17.8M 0.25%
84,865
-1,484
-2% -$316K
PHR icon
92
Phreesia
PHR
$654M
$17M 0.24%
680,153
+99,655
+17% +$2.19M
ILMN icon
93
Illumina
ILMN
$28B
$16M 0.23%
89,299
+8,209
+10% +$2.1M
EPIX
94
DELISTED
ESSA Pharma
EPIX
$15.8M 0.22%
5,009,714
-25,100
-0.5% -$140K
AVTR icon
95
Avantor
AVTR
$7.35B
$15.6M 0.22%
503,007
-9,209
-2% -$287K
PRVA icon
96
Privia Health
PRVA
$3.34B
$15.1M 0.21%
519,876
-5,124
-1% -$130K
WVE icon
97
Wave Life Sciences
WVE
$1.11B
$14.6M 0.21%
4,494,458
-68,400
-1% -$132K
TDOC icon
98
Teladoc Health
TDOC
$1.71B
$13.8M 0.2%
416,112
+52,896
+15% +$2.25M
AMGN icon
99
Amgen
AMGN
$197B
$12.4M 0.18%
50,959
-2,841
-5% -$696K
SRRK icon
100
Scholar Rock
SRRK
$6.26B
$11.8M 0.17%
2,152,025
-32,400
-1% -$233K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2022 Portfolio in Review

As of Q2 2022, Bellevue Group held 187 positions worth $7.07B, down 18% from $8.61B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q2 2022 filing shows 10 new, 57 increased, 82 reduced and 15 closed positions. Its largest new stake was Celldex Therapeutics: 925,000 shares worth $24.9M. The largest sale was Elevance Health, an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2022 buy was Celldex Therapeutics: 925,000 shares worth $24.9M.
  • Bellevue Group added most to Intuitive Surgical in Q2 2022, an estimated $67.9M increase.
  • Bellevue Group's biggest Q2 2022 reduction was Elevance Health, cutting an estimated $100M.
  • Bellevue Group fully exited Dentsply Sirona in Q2 2022, selling an estimated $7.83M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.07B portfolio in Q2 2022.
  • Bellevue Group opened 10 new positions and closed 15 in Q2 2022.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.